Meropenem Cf (Meropenem Anhydrous)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, preventing the cross‑linking of peptidoglycan strands. This leads to loss of cell‑wall integrity, osmotic lysis, and bacterial death, providing broad activity against many Gram‑negative, Gram‑positive, and anaerobic organisms.

The prescribed dose of Meropenem Cf is determined by the treating physician based on the type and severity of infection, patient weight, renal function, and local susceptibility patterns. Dosing regimens are individualized and should follow the prescriber's instructions.

Safety data for Meropenem in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the prescribing clinician.

To order Meropenem Cf, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Meropenem shares the broad‑spectrum activity of the carbapenem class but offers a slightly higher stability against certain β‑lactamases compared with imipenem and a lower risk of seizures than ertapenem. Choice among carbapenems depends on local resistance patterns, dosing convenience, and patient‑specific factors.

Meropenem Cf should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen. After reconstitution, the solution should be used within the time frame specified in the product labeling and kept at controlled room temperature if not administered immediately.

Meropenem Cf is supplied as a sterile powder for reconstitution. After adding the appropriate diluent, the solution is administered intravenously over a prescribed infusion period, typically 15–30 minutes, under aseptic conditions by qualified healthcare personnel.

Serious adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, severe hypersensitivity reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Prompt recognition and medical intervention are essential if any of these occur.

Meropenem Cf is contraindicated in individuals with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for patients with uncontrolled seizure disorders, severe renal impairment without dose adjustment, and those receiving valproic acid without appropriate monitoring.